Allergy News and Research

RSS

The term allergy encompasses a wide range of conditions; it is not a disease in itself. In 1906 Clemens von Pirquet was the first to describe allergies as a changed or altered reaction of the immune system in response to exposure to foreign proteins. These days the term allergy – medically termed hypersensitivity, signifies an exaggerated reaction to foreign substances.

Allergic reactions to insulin have declined and Continuous Subcutaneous Insulin Infusion could reduce them further

A review of published research from the University of Liege, Belgium, reveals a decline in the number of people experiencing allergic reactions to insulin. This is largely due to better purification of animal insulin and the introduction of human recombinant insulin.

8 Jan 2007

DNA vaccine for H5N1 avian influenza enters human trial

The first human trial of a DNA vaccine designed to prevent H5N1 avian influenza infection began on December 21, 2006, when the vaccine was administered to the first volunteer at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD.

3 Jan 2007

An effective malaria vaccine by 2025

A report by the world's leading international health organizations today calls for joint action to accelerate the development and licensing of a highly effective malaria vaccine.

4 Dec 2006

The role of gut worms in allergies

Gut parasites could hold the key to increasingly common conditions such as eczema, asthma and hay fever, according to scientists at The University of Nottingham.

2 Dec 2006

New approaches to expanding HIV testing

Nearly 300 U.S. physicians, government health officials and HIV/AIDS advocates on Wednesday gathered in Washington, D.C., for a two-day meeting that focuses on new approaches to expanding HIV testing in the nation and its potential effect on the health system, Reuters Health reports.

2 Dec 2006

Interruptions in antiretroviral treatment increases risk of developing AIDS-related diseases

Interruptions in an HIV-positive person's antiretroviral treatment regimen can increase the risk of developing AIDS-related diseases and sometimes can be fatal, according to a study published Thursday in the New England Journal of Medicine, the Los Angeles Times reports.

2 Dec 2006

MChip to detect H5N1

Scientists from the University of Colorado at Boulder and the Centers for Disease Control and Prevention (CDC) have developed an inexpensive "gene chip" test based on a single influenza virus gene that could allow scientists to quickly identify flu viruses, including avian influenza H5N1.

14 Nov 2006

Phase I clinical trial of experimental gene therapy to treat HIV shows encouraging results

The results of a Phase I clinical trial of an experimental gene therapy aimed at treating HIV indicate that the therapy is safe and effective and also might sustain viral loads, according to a study published on Monday in the online edition of the Proceedings of the National Academy of Sciences, the AP/Washington Post reports.

8 Nov 2006

The lifetime cost of current HIV care in the United States

"The Lifetime Cost of Current HIV Care in the United States," a major study appearing in the November 2006 issue of Medical Care, projects the cost of treatment for HIV-infected adults using current standards of care.

1 Nov 2006

Weill Cornell findings could foil two potential bioterror agents - viral peptide prevents deadly Hendra, Nipah viruses from infecting cells

Two lethal and easily transmitted viruses -- both potential bioterror agents -- may soon be much less dangerous, thanks to research led by scientists at Weill Cornell Medical College in New York City.

31 Oct 2006

FDA warns about risks of using decorative contact lenses

This Halloween season, the U.S. Food and Drug Administration (FDA) is again warning consumers about the serious risks of using decorative contact lenses without the appropriate involvement of an eye care professional.

30 Oct 2006

FDA approves Omnaris, new hay fever drug

The U.S. Food and Drug Administration (FDA) has announced the approval of Omnaris (ciclesonide) nasal spray, a new drug for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis, commonly known as hay fever, in adults and children 12 years of age and older.

23 Oct 2006

Important first step towards designing new therapies for shingles

A team of scientists at the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH), has identified a human protein that helps varicella-zoster virus, the cause of chickenpox and shingles, spread from cell to cell within the body.

20 Oct 2006

UT Southwestern looks at promising new medication that reduces the severity and frequency of asthma attacks

UT Southwestern Medical Center is one of a handful of top research institutions evaluating a promising new medication researchers hope can reduce the severity and frequency of asthma attacks in inner-city children, a population known to have a high prevalence of severe asthma.

20 Oct 2006

NC State researchers receive $3.5 million to tackle HIV

Researchers at North Carolina State University have received a $3.5 million grant from the National Institute of Allergy and Infectious Disease (NIAID) to develop mathematical and statistical models that will aid in designing new treatment strategies for HIV patients.

19 Oct 2006

Transport mechanism of bioactive molecule, S1P, identified

Virginia Commonwealth University researchers have identified how a bioactive molecule involved with allergy, inflammation and cancer is transported out of mast cells, according to findings published online this week in the Proceedings of the National Academy of Sciences.

17 Oct 2006

Vaccine that protects mice against 1918 influenza virus developed

Federal scientists have developed a vaccine that protects mice against the killer 1918 influenza virus. They also have created a technique for identifying antibodies that neutralize this virus, a tool that could help contain future pandemic flu strains.

17 Oct 2006

Updates on pandemic flu vaccine trials to be presented at 44th Annual IDSA meeting

Preliminary results from clinical trials testing two different pandemic flu vaccine approaches - one a prime-boost strategy using different subtypes of H5N1 vaccines, the other an H5N1 vaccine delivered into the skin (intradermal) rather than the muscle - will be presented at the 44th Annual Meeting of the Infectious Diseases Society of America.

16 Oct 2006

New York Times examines efforts to obtain FDA approval for Abraxane to treat earlier-stage cancer

The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.

5 Oct 2006

FDA approves FluLaval

The U.S. Food and Drug Administration (FDA) today approved FluLaval, an influenza vaccine to immunize people 18 years of age and older against the disease caused by strains of influenza virus judged likely to cause seasonal flu in the Northern Hemisphere in 2006-2007.

5 Oct 2006